Monday, June 3, 2024, Chicago, Illinois, 7:00 PM – 9:00 PM Central Time (8:00 PM – 10:00 PM Eastern Time)

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Metastatic Breast Cancer

A CME Hybrid Symposium Held in Conjunction with the 2024 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois
Phone: (312) 922-4400

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Aditya Bardia, MD, MPH
Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Division of Medical Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive
Cancer Center
Los Angeles, California

Harold J Burstein, MD, PhD
Institute Physician
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Professor Giuseppe Curigliano, MD, PhD
Clinical Director
Division of Early Drug Development
for Innovative Therapy
Co-Chair, Cancer Experimental
Therapeutics Program
Department of Oncology and Hemato-Oncology
University of Milano
European Institute of Oncology
Milano, Italy

Sara A Hurvitz, MD, FACP
Professor
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Head, Division of Hematology/Oncology
UW Medicine
Seattle, Washington


Joyce O’Shaughnessy, MD
Celebrating Women Chair
in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Dallas, Texas

Hope S Rugo, MD
Professor of Medicine
Winterhof Family Professor of Breast Cancer
Director, Breast Oncology
and Clinical Trials Education
Medical Director, Cancer Infusion Services
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Lilly, Merck, and Stemline Therapeutics Inc.
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

Discussion Topics

  • MODULE 1: Optimizing the Management of HER2-Positive Metastatic Breast Cancer (mBC)
  • MODULE 2: Individualized Selection of Up-Front Therapy for Patients with HR-Positive, HER2-Negative mBC
  • MODULE 3: Selection and Sequencing of Treatment for Patients with HR-Positive, HER2-Negative Disease Who Experience Disease Progression on CDK4/6 Inhibition
  • MODULE 4: Current and Future Role of HER2-Targeted Therapy in the Management of HER2-Low Disease
  • MODULE 5: Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer
  • MODULE 6: Current and Future Strategies for the Care of Patients with Endocrine-Refractory HR-Positive mBC

Target Audience
This activity is intended for medical and radiation oncologists, hematologists, hematology-oncology fellows, general and breast surgeons and other healthcare providers involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Evaluate biological, patient- and treatment-related factors to personalize the selection and sequencing of therapy for metastatic breast cancer (mBC).
  • Appraise published efficacy and safety data from randomized clinical trials evaluating CDK4/6 inhibitors for HR-positive mBC to appropriately counsel patients regarding the optimal clinical use of these agents.
  • Recognize the frequency of PIK3CA/AKT1/PTEN alterations in patients with HR-positive mBC, and employ evidence-based approaches designed to target these aberrations in progressive HR-positive, HER2-negative disease.
  • Understand the mechanism of action, published research findings with and current and future clinical role of oral selective estrogen receptor degraders for patients with relapsed/refractory HR-positive mBC.
  • Evaluate published research findings to effectively inform the selection and sequencing of available therapeutic agents and regimens for patients with HER2-positive mBC.
  • Review published research data supporting the use of chemotherapy in combination with anti-PD-1/PD-L1 antibodies for patients with metastatic triple-negative breast cancer (mTNBC), and use this information to make appropriate treatment recommendations.
  • Discuss available research findings establishing the efficacy of PARP inhibitors in patients with mBC harboring BRCA or other homologous recombination repair pathway mutations, and appropriately identify candidates for treatment with these agents.
  • Appreciate the incidence, characteristics and clinical relevance of HER2-low mBC, and understand available management approaches for patients with this subset of the disease.
  • Interrogate published Phase III research findings documenting the efficacy of TROP2-directed antibody-drug conjugates in patients with mBC to determine the current and future clinical applicability of these approaches.
  • Assess the biological rationale for, early data with and ongoing clinical trials evaluating other novel agents and treatment strategies under development for mBC.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Bardia — Consulting Agreements and Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Menarini Group, Merck, Novartis, Pfizer Inc, Radius Health Inc, Sanofi. Prof Curigliano — Advisory Committees and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Lilly, Menarini Group, Merck, Novartis, Seagen Inc; Contracted Research: Merck; Data and Safety Monitoring Board/Committee: Roche Laboratories Inc; Scientific Board: Ellipses Pharma; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Lilly, Merck, Novartis, Pfizer Inc. Dr O'Shaughnessy — Advisory Committees and Consulting Agreements: AbbVie Inc, Agendia Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, Carrick Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Fishawack Health, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Ontada, Pfizer Inc, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis, Sanofi, Seagen Inc, Stemline Therapeutics Inc. Dr Rugo — Consulting Agreements: Daiichi Sankyo Inc, Eisai Inc, Napo Pharmaceuticals Inc, Viatris; Contracted Research: Ambrx, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Stemline Therapeutics Inc. Additional faculty to be announced.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Lilly, Merck, and Stemline Therapeutics Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Grand Ballroom (Level 2)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

This activity is intended for medical and radiation oncologists, hematologists, hematology-oncology fellows, general and breast surgeons and other healthcare providers involved in the treatment of breast cancer.

There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.

NOTICE:
Registration for this event is independent of registration for the 2024 ASCO Annual Meeting.

IN-PERSON Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.